Evidence map›Paper›PMID 27713118›Full record

ArticleOncotarget2016

Exploring the interactions of the RAS family in the human protein network and their potential implications in RAS-directed therapies.

Anibal Bueno, Ian Morilla, Diego Diez, Aurelio A Moya-Garcia, José Lozano, Juan A G Ranea

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 6 institutions in 4 countries.

Anibal BuenoDepartmento de Biología Molecular y Bioquímica, Universidad de Málaga, Málaga 29071, Spain.
Ian MorillaInstitute of Molecular Life Sciences, University of Zurich, Zurich CH-8057, Switzerland.
Diego DiezQuantitative Immunology Research Unit, World Premier International Immunology Frontier Research Center, Osaka University, Osaka 565-0871, Japan.
Aurelio A Moya-GarciaInstitute of Structural and Molecular Biology, University College London, London WC1E 6BT, UK.
José LozanoDepartmento de Biología Molecular y Bioquímica, Universidad de Málaga, Málaga 29071, Spain.
Juan A G RaneaDepartmento de Biología Molecular y Bioquímica, Universidad de Málaga, Málaga 29071, Spain.
Centro de Investigación Biomédica en Red · ESInstituto de Investigación Biomédica de Málaga · ESOsaka International University · JPUniversidad de Málaga · ESUniversity College London · GBUniversity of Zurich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

RAS proteins are the founding members of the RAS superfamily of GTPases. They are involved in key signaling pathways regulating essential cellular functions such as cell growth and differentiation. As a result, their deregulation by inactivating mutations often results in aberrant cell proliferation and cancer. With the exception of the relatively well-known KRAS, HRAS and NRAS proteins, little is known about how the interactions of the other RAS human paralogs affect cancer evolution and response to treatment. In this study we performed a comprehensive analysis of the relationship between the phylogeny of RAS proteins and their location in the protein interaction network. This analysis was integrated with the structural analysis of conserved positions in available 3D structures of RAS complexes. Our results show that many RAS proteins with divergent sequences are found close together in the human interactome. We found specific conserved amino acid positions in this group that map to the binding sites of RAS with many of their signaling effectors, suggesting that these pairs could share interacting partners. These results underscore the potential relevance of cross-talking in the RAS signaling network, which should be taken into account when considering the inhibitory activity of drugs targeting specific RAS oncoproteins. This study broadens our understanding of the human RAS signaling network and stresses the importance of considering its potential cross-talk in future therapies.

Indexed as

Protein Interaction MapsAmino Acid SequenceCarrier ProteinsComputational BiologyConserved SequenceDatabases, ProteinHumansMutationNeoplasmsPhylogenyProtein BindingProtein Interaction Mappingras ProteinsSignal TransductionCarrier Proteinsras ProteinscancernetworkRassignalingtherapy

Identifiers

PMID27713118
PMCPMC5342780
OpenAlexW2528040086

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.